

Edgar Filing: QUADRAMED CORP - Form 8-K

QUADRAMED CORP  
Form 8-K  
August 14, 2002

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

AUGUST 14, 2002  
Date of report (date of earliest event reported)

QUADRAMED CORPORATION  
(Exact Name of Registrant as Specified in Its Charter)

Delaware	0-21031	52-1992861
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

22 PELICAN WAY, SAN RAFAEL, CALIFORNIA	94901
(Address of Principal Executive Offices)	(Zip Code)

(415) 482-2100  
(Registrant's Telephone Number, Including Area Code)

ITEM 5. Other Items.

QuadraMed Corporation ("QuadraMed") announced new developments regarding its intention to restate prior period financial statements. Late yesterday, in the process of finalizing the restated financial statements, it became apparent to QuadraMed that information crucial to the re-statement of prior years is not presently available and that the re-statement cannot be completed in time to meet the extended filing deadline of August 19, 2002 for its Form 10-Q. QuadraMed is in the process of notifying the SEC and Nasdaq of these developments.

QuadraMed will develop a plan for completing the re-statement process. QuadraMed expects to make further announcements regarding the status of these efforts in the coming days.

## Edgar Filing: QUADRAMED CORP - Form 8-K

ITEM 7. Exhibit.

Exhibit No.	Description
99.1	QuadraMed Press Release dated August 14, 2002 entitled, "Quadramed Provides Further Restatement Information."

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 14, 2002

QUADRAMED CORPORATION

By: /s/ Michael H. Lanza

-----  
Michael H. Lanza  
Executive Vice President  
and Corporate Secretary

EXHIBIT 99.1

QUADRAMED CORPORATION  
(Logo)

FOR IMMEDIATE RELEASE

CONTACT: Jack R. Ripsteen, Director of Investor Relations  
415/482-2211  
jriptideen@quadramed.com

### QUADRAMED PROVIDES FURTHER RESTATEMENT INFORMATION

San Rafael, California - Wednesday, August 14, 2002 - QuadraMed Corporation (Nasdaq: QMDC) today announced new developments regarding its intention to restate prior period financial statements. Late yesterday, in the process of finalizing the restated financial statements, it became apparent to the Company that information crucial to the re-statement of prior years is not presently available and that the re-statement cannot be completed in time to meet the extended filing deadline of August 19, 2002 for its Form 10-Q. The Company is in the process of notifying the SEC and Nasdaq of these developments.

QuadraMed will develop a plan for completing the re-statement process. QuadraMed expects to make further announcements regarding the status of these efforts in the coming days.

Cautionary Statement on Risks Associated With Forward-Looking Statements  
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. The words "believe," "expect," "anticipate," "intend," "plan," "estimate," "may," "should," "could," and similar expressions are intended to identify such statements. Forward-looking statements are not guarantees of future performance and are to be interpreted only as of the date on which they are made. QuadraMed

## Edgar Filing: QUADRAMED CORP - Form 8-K

undertakes no obligation to update or revise any forward-looking statement.

Important factors that could cause QuadraMed's actual results to differ materially from these forward-looking statements include, but are not limited to, the following: (i) QuadraMed's quarterly operating results may vary, (ii) QuadraMed's stock price may be volatile, (iii) QuadraMed's investments are subject to market risk, (iv) QuadraMed faces product development risks from rapid technological changes, (v) QuadraMed's products may be subject to bugs and other errors, (vi) QuadraMed's intellectual property and technology may be subject to infringement claims or be infringed upon, (vii) QuadraMed's products and services, particularly those sold to government entities and those sold to customers receiving government reimbursement, are subject to scrutiny, regulation, and possible future regulation by state and federal governments; (viii) increased competition for QuadraMed's products and services, and (ix) QuadraMed may need to use its cash balances to repurchase or redeem its subordinated convertible debentures. QuadraMed does not intend this list of important factors to be exhaustive and advises investors that it discusses other risks and uncertainties that could cause QuadraMed's actual results to differ from these forward-looking statements in its periodic reports filed with the Securities and Exchange Commission ("SEC"). These SEC filings can be accessed through the Investor Relations section of our website, [www.quadramed.com](http://www.quadramed.com), or through the SEC's EDGAR Database at [www.sec.gov](http://www.sec.gov) (QuadraMed has EDGAR CIK No. 0001018833).

### About QuadraMed Corporation

QuadraMed is dedicated to developing information technology and providing consulting services that help healthcare professionals deliver outstanding patient care with optimum efficiency. Offering real-world solutions for every aspect of acute care information management, QuadraMed has four main product lines: Affinity(R) Healthcare Information System, Quantim(R) Health Information Management Software and Services, Complysource(R) Compliance Solutions, and Chancellor(TM) Financial Products and Services. Behind our products and services are nearly 1000 professionals whose healthcare experience has earned QuadraMed the trust and loyalty of its many customers. To find out more about QuadraMed, visit [www.quadramed.com](http://www.quadramed.com).

Note to Editors: QuadraMed, Affinity, Quantim, and Complysource are registered trademarks of QuadraMed Corporation. Chancellor is a trademark of QuadraMed Corporation. All other trademarks and registered trademarks are the properties of their respective holders.

###